Torsdag 26 December | 11:34:27 Europe / Stockholm

Kalender

Tid*
2025-03-06 N/A Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2024-06-18 16:25:00

Nightingale Health Plc

Company release

18 June 2024 at 5:25 p.m. (EEST)

Nightingale Health Plc ("Nightingale Health") has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Cor Group Oy's ownership of shares exceeds 10% of all shares and votes exceed 10% of all votes in Nightingale Health. Cor Group Oy's ownership and votes exceeded the notification threshold before 19 April 2024.

The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the Securities Markets Act entered into force on 19 April 2024, according to which the flagging obligation shall also apply to shareholders and persons comparable to shareholders of companies listed on the Nasdaq First North Growth Market Finland. In case a proportion of holdings or votes is at least five percent on 19 April 2024 when the amendment entered into force, a flagging notification shall be made within two months from the commencement of the amendment.

The flagging has been made in accordance with the transitional provisions applicable in connection with the amendment of the law and concerns the holdings in force at the time of the entry into force of the amendment on 19 April 2024.

Total positions of person subject to the notification obligations:

+-------------+------+-----------+---------+----------------------+
| |% of |% of shares|Total of |Total number of shares|
| |shares|and voting |both in %|and voting rights of |
| |and |rights | |issuer |
| |voting|through | | |
| |rights|financial | | |
| | |instruments| | |
+-------------+------+-----------+---------+----------------------+
|Resulting |10.15%|- |10.15% of|60,918,459 shares |
|situation on |of | |shares | |
|the date |shares| | |245,092,975 |
|on which | | |12.69% of| |
|threshold was|12.69%| |voting |voting rights |
|reached |of | |rights | |
| |voting| | | |
| |rights| | | |
+-------------+------+-----------+---------+----------------------+

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

+------------+------------+---------------+------------------------+----+
|A: Shares |
|and voting |
|rights |
+------------+------------+---------------+------------------------+----+
|Class/type |Number of |% of shares and voting rights|
|of shares |shares and | |
| |voting | |
|ISIN code |rights | |
+------------+------------+---------------+------------------------+----+
|Direct(SMA |Indirect(SMA|Direct(SMA 9:5)|Indirect(SMA 9:6 ja 9:7)|
|9:5) |9:6 ja 9:7) | | |
+------------+------------+---------------+------------------------+----+
|HEALTH |3,412,591 |- |5.60% of shares |- |
| | | | | |
|FI4000490875| | |1.39% of voting rights | |
+------------+------------+---------------+------------------------+----+
|HEALTHA |2,769,802 |- |4.55% of shares |- |
|FI4000490867| | | | |
| | | |11.30% of voting rights | |
+------------+------------+---------------+------------------------+----+
|SUBTOTAL A |6,182,393 |- |10.15% of shares |- |
| | | | | |
| | | |12.69% of voting rights | |
+------------+------------+---------------+------------------------+----+

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com